Related Experiment Video
Updated: Jun 29, 2026
08:27
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
Preventing Alzheimer's disease : separating fact from fiction
Mary Sano1, Hillel Grossman, Kathleen Van Dyk
1The Alzheimer Disease Research Center of Mount Sinai School of Medicine, New York, New York, USA. mary.sano@mssm.edu
CNS Drugs
|October 9, 2008
Summary
Alzheimer's disease treatments are evolving, with recent approvals for symptomatic relief. Future research focuses on novel approaches like immunotherapy to target underlying pathology and prevent disease progression.
Area of Science:
- Neuroscience
- Gerontology
- Pharmacology
Background:
- Alzheimer's disease (AD) poses a growing threat to the aging population.
- Existing symptomatic treatments include cholinesterase inhibitors and NMDA receptor antagonists.
- Previous trials explored antioxidants, NSAIDs, and supplements with limited success.
Purpose of the Study:
- To review evidence from completed clinical trials for Alzheimer's disease treatments.
- To assess ongoing studies and propose future research directions.
- To explore novel therapeutic strategies targeting AD pathology.
Main Methods:
- Review of completed placebo-controlled clinical trials for AD.
- Analysis of observational studies and animal models.
- Examination of ongoing trials for immunotherapy and secretase modulation.
Main Results:
- Symptomatic treatments for AD have been approved in the last two decades.
- Many trials for AD prevention and treatment yielded disappointing results.
- Emerging therapies targeting amyloid burden show promise.
Conclusions:
- Continued investigation into novel Alzheimer's disease treatments is crucial.
- Immunotherapy and secretase modulation represent promising future directions.
- Further research is needed to establish effective AD prevention and treatment strategies.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.